Remix Therapeutics

Additional undisclosed programs RD CNS diseases, genetic disorders, undisclosed

Remix Therapeutics is developing small molecule therapeutics to alter the expression of mRNA and proteins driving disease. RNA processing is a tightly regulated process that impacts the abundance of proteins synthesized. Using their REMaster drug discovery platform, Remix is identifying druggable target sites and active chemical matter to advance novel therapies that can alter RNA expression and restore functional levels. The proprietary platform combines data science and bioinformatics to identify modifiable sites with multiplexed high-throughput screening technologies that uses their chemical library enriched for compounds that can interact with RNA processing machinery. Remix is currently building a pipeline of RNA processing modulators across oncology and neurodegeneration.